scholarly journals Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Kimberly Aderhold ◽  
Lisa Carpenter ◽  
Krysta Brown ◽  
Anthony Donato

Primary Cutaneous Peripheral T-Cell Lymphoma NOS (PTL-NOS) is a rare, progressive, fatal dermatologic disease that presents with features similar to many common benign plaque-like skin conditions, making recognition of its distinguishing features critical for early diagnosis and treatment (Bolognia et al., 2008). A 78-year-old woman presented to ambulatory care with a single 5 cm nodule on her shoulder that had developed rapidly over 1-2 weeks. Examination was suspicious for malignancy and a biopsy was performed. Biopsy results demonstrated CD4 positivity, consistent with Mycosis Fungoides with coexpression of CD5, CD47, and CD7. Within three months her cancer had progressed into diffuse lesions spanning her entire body. As rapid progression is usually uncharacteristic of Mycosis Fungoides, her diagnosis was amended to PTL-NOS. Cutaneous T-Cell Lymphoma (CTCL) should be suspected in patients with patches, plaques, erythroderma, or papules that persist or multiply despite conservative treatment. Singular biopsies are often nondiagnostic, requiring a high degree of suspicion if there is deviation from the anticipated clinical course. Multiple biopsies are often necessary to make the diagnosis. Physicians caring for patients with rapidly progressive, nonspecific dermatoses with features described above should keep more uncommon forms of CTCL in mind and refer for early biopsy.

2017 ◽  
Vol 10 (1) ◽  
pp. 328-332 ◽  
Author(s):  
Kayo Tanita ◽  
Taku Fujimura ◽  
Yota Sato ◽  
Takanori Hidaka ◽  
Sadanori Furudate ◽  
...  

Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL). Since it is difficult to distinguish AI from ichthyosiform mycosis fungoides, to select the treatment for CTCL with ichthyosis-like appearance and to evaluate its efficacy is sometimes challenging. In this report, we describe a case of primary cutaneous peripheral T-cell lymphoma not otherwise specified presenting AI successfully treated with oral bexarotene. In the present case, the administration of oral bexarotene was not only effective for lymphoma cells infiltrating ulcers and nodules, but it also eliminated AI.


2020 ◽  
Vol 23 ◽  
pp. S693-S694
Author(s):  
J. Scarisbrick ◽  
F. Schmidt ◽  
M.M. Turini ◽  
P. D'agostino ◽  
D. Summers ◽  
...  

Author(s):  
Timothy J. Voorhees ◽  
Edith V. Bowers ◽  
Christopher R. Kelsey ◽  
Yara Park ◽  
Anne W. Beaven

2004 ◽  
Vol 28 (5) ◽  
pp. 670-675 ◽  
Author(s):  
Eung Yeop Kim ◽  
Sam Soo Kim ◽  
Jae Wook Ryoo ◽  
Dong Gyu Na ◽  
Hong Gee Roh ◽  
...  

Blood ◽  
1996 ◽  
Vol 88 (8) ◽  
pp. 3004-3009 ◽  
Author(s):  
BA Pancake ◽  
EH Wassef ◽  
D Zucker-Franklin

Although most patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cell lymphotropic virus-I or -II (HTLV-I/II) when tested by assays that measure only antibodies to the viral structural proteins, the majority of such patients harbor HTLV-I-related pol and tax proviral sequences that encode proteins not included in routinely used serologic tests. Tax mRNA has also been detected in their peripheral blood mononuclear cells (PBMC). Therefore, it seemed possible that these patients have antibodies to the tax protein. To investigate this, enzyme-linked immunosorbent assays (ELI-SAs) and Western blot assays were set up, using as antigens the full-length HTLV-I tax cloned from the prototypic HTLV-I-infected cell line, C91PL, and from PBMC of a MF patient, as well as a synthetic peptide made to the carboxy-terminal 20 amino acids of tax-I. Of 60 MF patients whose PBMC were shown to be positive for tax proviral DNA and mRNA, 50 (83%) were shown to have tax antibodies. The antigen derived from the MF patient was most useful in detecting such antibodies. These results demonstrate the need for including other HTLV-related antigens in addition to gag and env in serologic tests used to identify HTLV-infected individuals. The findings underscore the fact that individuals considered seronegative on the basis of currently used tests can be infected with HTLV.


Sign in / Sign up

Export Citation Format

Share Document